Oncology Institute, Inc. (TOI) - Dilution Analysis

10-Q filing | 101.8M shares outstanding

10-K filing | 92.4M shares outstanding

10-Q filing | 97.5M shares outstanding

10-Q filing | 93.2M shares outstanding

S-3/A filing: The Oncology Institute, Inc. may offer and sell up to $50,000,000 in the aggregate of its common stock from time to time in one or more offerings as well as shares of common stock having an aggregate offering price of up to $15,000,000 in an at-the-market offering that may be made from time to time through or to its sales agent, BTIG, as agent.

S-3 filing: The Oncology Institute, Inc. may offer and sell up to $50,000,000 in the aggregate of its common stock from time to time. An "at-the-market" offering may be made from time to time through or to the sales agent, BTIG, as agent, for up to $15,000,000.

10-Q filing | 89.2M shares outstanding

S-3 filing: This S-3 filing pertains to the resale of up to 27,924,611 shares of common stock by selling securityholders, including shares presently issued and outstanding, issuable upon the exercise of outstanding pre-funded warrants and common warrants, and issuable upon the conversion of Series A Common Equivalent Convertible Preferred Stock.

10-K filing | 75.0M shares outstanding

10-Q filing | 75.5M shares outstanding

10-Q filing | 74.7M shares outstanding

10-Q filing | 74.2M shares outstanding

10-K filing | 73.7M shares outstanding

10-Q filing | 73.5M shares outstanding

8-K filing: The Oncology Institute, Inc. authorized a share repurchase program to purchase up to 2 million shares of its common stock at a price not to exceed $1.00 per share, with repurchased shares returned to authorized but unissued status.

10-Q filing | 74.1M shares outstanding

8-K filing: The Oncology Institute, Inc. authorized a share repurchase program for up to 5 million shares of its common stock at a price not to exceed $0.75 per share, with repurchased shares returned to authorized but unissued status. A limited consent agreement with Deerfield Partners, L.P. permits the repurchase by the Company on or prior to June 16, 2023, of up to 5,000,000 shares of the Company's Common Stock in one or more open market or negotiated purchases, in each case at price per share not to exceed $0.75.

10-Q filing | 73.4M shares outstanding

10-K filing | 72.8M shares outstanding

POS AM filing: The Oncology Institute, Inc. is offering 1,227,161 shares of common stock by the Registered Holders. The company will not receive any proceeds from the sale of shares.

POS AM filing: Extracted offering data from POS AM filing on 2023-01-30.

POS AM filing: This POS AM filing relates to the offering of up to 20,459,040 shares of common stock issuable upon conversion or exercise of Convertible Notes or DF Warrants by the Registered Holders.

10-Q filing | 72.2M shares outstanding

S-1/A filing: This prospectus relates to the offer and sale from time to time by the selling securityholders of up to 20,459,040 shares of our common stock, issuable upon the conversion or exercise of or otherwise pursuant to the Convertible Notes or DF Warrants issued in connection with the Facility Agreement.

S-1 filing: The Oncology Institute, Inc. is offering up to 20,459,040 shares of common stock issuable upon the conversion or exercise of Convertible Notes or DF Warrants by selling securityholders.

8-K filing: The Oncology Institute, Inc. entered into a Facility Agreement with Deerfield Partners, L.P. for the issuance and sale of $110 million of 4.0% secured senior convertible notes, which are convertible into common stock at an initial conversion price of $8.567 per share, and also provides for the issuance of warrants to purchase common stock upon prepayment of obligations under the Facility Agreement. ($107.0M proceeds)

10-Q filing | 73.0M shares outstanding

S-1 filing: This S-1 filing relates to the offer and sale from time to time by the selling securityholders of up to an aggregate of 1,342,076 shares of common stock.

8-K filing: The Oncology Institute, Inc. authorized a share repurchase program of up to $20 million of its common stock and agreed to repurchase 1,900,000 shares at $6.00 per share from affiliates of Dr. Richy Agajanian in a privately-negotiated transaction. ($11.4M proceeds)

10-Q filing | 73.3M shares outstanding

POS AM filing: This is a POS AM filing for up to 90,477,403 shares of common stock and 3,177,542 warrants.

10-K filing | 66.2M shares outstanding

S-1/A filing: This S-1/A filing registers for resale (a) up to 8,927,543 shares of common stock issuable upon the exercise of warrants, (b) up to 91,009,656 shares of common stock held by selling securityholders, and (c) up to 3,177,543 warrants held by selling securityholders.

S-1 filing: This S-1 filing includes the issuance of up to 8,927,543 shares of common stock upon exercise of warrants, and the offer and sale of 86,733,593 shares of common stock and 3,177,543 warrants by selling securityholders.

10-Q filing | 5.8M shares outstanding

10-Q filing | 2.9M shares outstanding

8-K filing: DFP Healthcare Acquisitions Corp. entered into a merger agreement with TOI Parent, Inc., involving First Merger Sub and Second Merger Sub, with DFP to be renamed The Oncology Institute, Inc. Additionally, DFP entered into subscription agreements to sell shares of DFP Class A Common Stock. ($275.0M proceeds)

10-Q filing | 23.0M shares outstanding

10-K filing | 5.8M shares outstanding

10-Q filing | 23.0M shares outstanding

10-Q filing | 23.0M shares outstanding

10-Q filing | 23.0M shares outstanding

8-K filing: DFP Healthcare Acquisitions Corp. consummated its initial public offering of 23,000,000 units at $10.00 per unit, generating gross proceeds of $230,000,000, and completed a private sale of 3,733,334 warrants to DFP Sponsor LLC at $1.50 per warrant, generating gross proceeds of $5,600,000. ($235.6M proceeds)

8-K filing: DFP Healthcare Acquisitions Corp. consummated its initial public offering of 23,000,000 Units at $10.00 per Unit, generating gross proceeds of $230,000,000 and completed the private sale of 3,733,334 warrants to DFP Sponsor LLC at $1.50 per warrant, generating gross proceeds of $5,600,000. ($235.6M proceeds)

S-1/A filing: S-1/A filing on 2020-03-04 describes units containing warrants exercisable for Class A common stock with an exercise price of $11.50 per share.

S-1 filing: Initial public offering of units, each consisting of one share of Class A common stock and one-fourth of one redeemable warrant, with the business purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.